Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

607 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.
Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. Nazha A, et al. Among authors: beran m. Front Oncol. 2013 Sep 6;3:218. doi: 10.3389/fonc.2013.00218. eCollection 2013. Front Oncol. 2013. PMID: 24032106 Free PMC article.
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.
Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Ravandi F, et al. Among authors: beran m. Leuk Res. 2010 Jun;34(6):752-6. doi: 10.1016/j.leukres.2009.10.001. Epub 2009 Oct 29. Leuk Res. 2010. PMID: 19878996 Free PMC article.
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, Pierce SA, Thomas DA, Kantarjian HM. Estey EH, et al. Among authors: beran m. Blood. 2002 Jun 15;99(12):4343-9. doi: 10.1182/blood.v99.12.4343. Blood. 2002. PMID: 12036860 Free article. Clinical Trial.
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Thomas DA, et al. Among authors: beran m. Blood. 2004 Jun 15;103(12):4396-407. doi: 10.1182/blood-2003-08-2958. Epub 2003 Oct 9. Blood. 2004. PMID: 14551133 Free article. Clinical Trial.
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Thomas DA, et al. Among authors: beran m. Blood. 2004 Sep 15;104(6):1624-30. doi: 10.1182/blood-2003-12-4428. Epub 2004 Jun 3. Blood. 2004. PMID: 15178574 Free article. Clinical Trial.
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Kantarjian H, et al. Among authors: beran m. Cancer. 2004 Dec 15;101(12):2788-801. doi: 10.1002/cncr.20668. Cancer. 2004. PMID: 15481055 Free article. Clinical Trial.
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H. Cortes J, et al. Among authors: beran m. J Clin Oncol. 2005 Apr 20;23(12):2805-12. doi: 10.1200/JCO.2005.09.005. Epub 2005 Feb 22. J Clin Oncol. 2005. PMID: 15728224 Clinical Trial.
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Wierda W, et al. Among authors: beran m. J Clin Oncol. 2005 Jun 20;23(18):4070-8. doi: 10.1200/JCO.2005.12.516. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767647
607 results